新日恆力(600165.SH)股東陳豪進減持684.7萬股
格隆匯8月14日丨新日恆力(600165.SH)公佈,股東陳豪進在減持實施前持有公司無限售流通股份5092.4萬股,佔公司總股本的7.44%。2019年7月31日至2019年8月5日,股東陳豪進通過大宗交易的方式減持公司1369萬股股份,佔公司總股本1.99%。
陳豪進計劃自2019年7月30起至2020年1月22日通過集中競價的方式以3.5~4.1元/股的價格區間減持不超過684.7萬股股份。
股東陳豪進自2019年7月30日至8月14日通過集中競價的方式以3.86~4.03元/股的價格區間共減持公司股票684.7萬股,佔公司總股本的0.999732%,本次減持計劃實施完畢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.